Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy

Article Properties
Cite
David, Kevin A., and Joel Picus. “Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy”. American Journal of Clinical Oncology, vol. 28, no. 3, 2005, pp. 277-80, https://doi.org/10.1097/01.coc.0000158439.02724.5a.
David, K. A., & Picus, J. (2005). Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy. American Journal of Clinical Oncology, 28(3), 277-280. https://doi.org/10.1097/01.coc.0000158439.02724.5a
David KA, Picus J. Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy. American Journal of Clinical Oncology. 2005;28(3):277-80.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Medicine (General)
You May Also Like
Refrences
Title Journal Journal Categories Citations Publication Date
Ifosfamide-Induced Encephalopathy Southern Medical Journal
  • Medicine: Medicine (General)
  • Medicine: Internal medicine
  • Medicine: Medicine (General)
 6 2002
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature British Journal of Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 137 2000
Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy European Journal of Clinical Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 70 1996
Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. 1994
Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloracetaldehyde, and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemotherapy and Pharmacology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 1993
Refrences Analysis
Category Category Repetition
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens7
Medicine: Medicine (General)6
Medicine: Public aspects of medicine: Toxicology. Poisons2
Medicine: Therapeutics. Pharmacology2
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system2
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry2
Medicine: Internal medicine1
Medicine: Gynecology and obstetrics1
Medicine1
The category Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 7 is the most frequently represented among the references in this article. It primarily includes studies from Anticancer Research and Southern Medical Journal. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Title Journal Journal Categories Citations Publication Date
Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas Clinical Lymphoma Myeloma and Leukemia
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
  • Medicine: Medicine (General)
 2023
Ifosfamide - History, efficacy, toxicity and encephalopathy Pharmacology & Therapeutics
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
 2 2023
Ifosfamide-Induced Encephalopathy Successfully Prevented by Methylene Blue: A Pediatric Case Report and Review of the Literature Cureus 2023
Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity Immunologic Research
  • Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
 12 2022
Ifosfamide-Induced Neurotoxicity in Children with Solid Tumors: A Seven Year Retrospective Analysis of Incidence and Risk Factors

 Journal of Pediatric Hematology/Oncology Nursing
  • Medicine: Public aspects of medicine
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Nursing
  • Medicine: Medicine (General)
 2022
Citations Analysis
Category Category Repetition
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens30
Medicine: Medicine (General)24
Medicine: Therapeutics. Pharmacology22
Medicine: Public aspects of medicine: Toxicology. Poisons20
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs7
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system6
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry6
Medicine: Pediatrics5
Medicine: Internal medicine3
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy3
Medicine: Internal medicine: Special situations and conditions: Industrial medicine. Industrial hygiene2
Medicine: Public aspects of medicine2
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system: Psychiatry2
Medicine: Internal medicine: Special situations and conditions: Geriatrics1
Philosophy. Psychology. Religion: Psychology1
Medicine: Surgery1
Science: Biology (General)1
Science: Physics1
Medicine: Nursing1
Medicine: Gynecology and obstetrics1
The category Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 30 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Metabolism and Transport of Oxazaphosphorines and the Clinical Implications and was published in 2005. The most recent citation comes from a 2023 study titled Ifosfamide-Induced Encephalopathy Successfully Prevented by Methylene Blue: A Pediatric Case Report and Review of the Literature. This article reached its peak citation in 2010, with 7 citations. It has been cited in 44 different journals, 6% of which are open access. Among related journals, the Journal of Oncology Pharmacy Practice cited this research the most, with 9 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year